肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
临床试验招募
登录/注册
VIP特权
广告
广告加载中...

文章:

肝切除术治疗肝细胞癌患者总生存期的预后指标

Prognostic Indicators of Overall Survival in Hepatocellular Carcinoma Patients Undergoing Liver Resection

原文发布日期:7 April 2024

DOI: 10.3390/cancers16071427

类型: Article

开放获取: 是

 

英文摘要:

Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and the third contributor to malignancy-related deaths worldwide. The hepatic venous pressure gradient (HVPG), transient elastography-liver stiffness measurement (TE-LSM), and the association between TBS (tumor burden score), alpha-fetoprotein levels, and the Child–Pugh classification (TAC score) can serve as valuable prognostic indicators for these patients. Therefore, the main objective of our research was to analyze the prognostic value of the HVPG, TE-LSM, TBS, and TAC scores. An observational and survival study was conducted on 144 subjects. Our findings indicated that HVPG greater than 10 mmHg, AFP surpassing 400 ng/mL, an advanced C–P class, and low TAC score are independent predictors of overall survival. During the multivariate analysis, AFP serum levels and C–P class proved statistically significant. The present study revealed significant differences in overall survival between the two groups divided upon HVPG values and settled by the cutoff of 10 mmHg (p= 0.02). Moreover, by dividing the cohort into three groups based on the TAC score (very low, low, and moderate), statistically significant differences in overall survival were observed across the groups (p= 0.004).

 

摘要翻译: 

肝细胞癌(HCC)是原发性肝癌的主要类型,也是全球恶性肿瘤相关死亡的第三大原因。肝静脉压力梯度(HVPG)、瞬时弹性成像-肝脏硬度测量(TE-LSM)以及肿瘤负荷评分(TBS)、甲胎蛋白水平与Child-Pugh分级之间的关联(TAC评分)可作为这类患者有价值的预后指标。因此,本研究的主要目的是分析HVPG、TE-LSM、TBS和TAC评分的预后价值。我们对144名受试者进行了观察性生存研究。研究结果显示,HVPG大于10 mmHg、甲胎蛋白超过400 ng/mL、晚期Child-Pugh分级以及低TAC评分是总生存期的独立预测因素。在多变量分析中,甲胎蛋白血清水平和Child-Pugh分级具有统计学显著性。本研究发现,根据HVPG值以10 mmHg为界值分组的两组患者,其总生存期存在显著差异(p=0.02)。此外,根据TAC评分将队列分为三组(极低、低和中等),各组间的总生存期也观察到统计学显著差异(p=0.004)。

 

原文链接:

Prognostic Indicators of Overall Survival in Hepatocellular Carcinoma Patients Undergoing Liver Resection

广告
广告加载中...